Search
Dexloxiglumide
go.drugbank.com/drugs/DB04856InvestigationalDexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist in phase III testing by Rottapharm in Europe only, as U.S. trials have been discontinued. As the D-isomer of loxiglumide, it retains all pharmacological prop...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesVoacamine
go.drugbank.com/drugs/DB04877ExperimentalVoacamine is an alkaloid isolated from the bark of the Pescheria fuchsiae folia tree. It is an antimalarial drug approved for use in several African countries. Voacamine is also under investigation for use in modulating multidrug-resista...
Synonyms: Methyl 12-methoxy-13-(17-methoxy-17-oxovobasan-3alpha-yl)ibogamine-18-carboxylateCategories: P-glycoprotein inhibitorsCalanolide A
go.drugbank.com/drugs/DB04886InvestigationalCalanolide A is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) derived from a plant found in the Malaysian rain forest. A related compound, calanolide B, also has anti-HIV activity. Both drugs are being developed by Sarawak...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesBicifadine
go.drugbank.com/drugs/DB04889InvestigationalBicifadine (DOV-220075) is a nonopioid analgesic. It is an inhibitor of both the norepinephrine and serotonin transporters and an NMDA antagonist with a non-narcotic profile. Bicifadine was shown to have potent analgesic activity in vivo...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesMilnacipran
go.drugbank.com/drugs/DB04896ApprovedInvestigationalMilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression . Furthermore...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsRifalazil
go.drugbank.com/drugs/DB04934InvestigationalRifalazil is a derivative of the antibiotic rifamycin. It is being investigated by ActivBiotics for the treatment of various bacterial infections.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesLofexidine
go.drugbank.com/drugs/DB04948ApprovedInvestigationalLofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesGanaxolone
go.drugbank.com/drugs/DB05087ApprovedInvestigationalGanaxolone is the 3β-methylated synthetic analog of allopregnanolone, a metabolite of progesterone. Ganaxolone belongs to a class of compounds referred to as neurosteroids. Endogenous neurosteroids, which comprise certain metabolites of ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesTrabectedin
go.drugbank.com/drugs/DB05109ApprovedInvestigationalTrabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate Ecteinascidia turbinata and now produced synthetically. Trabectedin has a unique mechanism of action. I...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesProducts: TRABECTEDINA EVER PHARMA, Trabectedin EVER Pharma 1 mg Pulver für ein Konzentrat zur Herstellung einer InfusionslösungVIR201
go.drugbank.com/drugs/DB05110Experimentalis an experimental therapeutic vaccine currently in clinical trial. The aim of therapeutic vaccines is to augment the body's immune response to HIV and to delay or prevent progression to AIDS.